Document is current
Any future updates will be listed below
-
Authors
Li, Fengzhi http://orcid.org/0000-0002-2299-7951
Ling, Xiang
Chakraborty, Sayan
Fountzilas, Christos
Wang, Jianmin
Jamroze, Anmbreen
Liu, Xiaozhuo
Kalinski, Pawel
Tang, Dean G.
-
Funding
Funding for this research was provided by:
Pancreatic Cancer Action Network (20-65-FENG)
- License Information
-
More Information
Article History
Received: 20 June 2023
Accepted: 1 August 2023
First Online: 19 August 2023
Declarations
:
: This review article contains both animal model data and human cancer cell line data. The animal model work was performed under the IACUC-approved protocol (1192 M) and the other in vitro work for the ethics approval are not applicable.
: The data provided in this review article are from the Authors’ research team and all authors agree to publish these data.
: FL118 and FL118 core structure platform-based analogs will be further developed in Canget BioTekpharma LLC (ExternalRef removed), a start-up company spun off from Roswell Park Comprehensive Cancer Center (ExternalRef removed). FL and XL are two of the eighteen initial investors and own equity in Canget.
